These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23084547)

  • 1. Chronic kidney disease and percutaneous coronary interventions with drug-eluting stents: does the K/DOQI classification matter?
    Favaretto E; Valente L; Napodano M; Frigo AC; Buja P; Ronco F; Cruz DN; Xhaxho J; Naso P; Ronco C; Isabella G; Iliceto S; Tarantini G
    Int J Cardiol; 2013 Jun; 166(2):530-3. PubMed ID: 23084547
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Kersting S; Grumann T; Hummel J; Hauschke D; Bode C; Hehrlein C
    Crit Pathw Cardiol; 2012 Sep; 11(3):152-9. PubMed ID: 22825536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
    Miao Y; Yu-Jie Z; Zhi-Jian W; Dong-Mei S; Yu-Yang L; Ying-Xin Z; Fei G; Shi-Wei Y; De-An J
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):361-7. PubMed ID: 22419375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short and long term outcome of percutaneous coronary intervention with drug eluting stent and bare metal stent in patients with chronic kidney disease.
    Resmini C; Di Cuia M; Ballocca F; D'Ascenzo F; Bollati M; Moretti C; Omedè PL; Sciuto F; Gaita F; Sheiban I
    Minerva Cardioangiol; 2012 Dec; 60(6):573-80. PubMed ID: 23147435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents.
    Lee MS; Park KW; Kang SH; Sheiban I; Mahmud E; Thani KB; Cheng R; Cho JH; Jin DK; Gwon HC; Chae IH; Aragon J; Gillis K; Stone GW; Kim HS
    J Invasive Cardiol; 2012 Jul; 24(7):316-9. PubMed ID: 22781468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion.
    Valenti R; Vergara R; Migliorini A; Parodi G; Carrabba N; Cerisano G; Dovellini EV; Antoniucci D
    J Am Coll Cardiol; 2013 Feb; 61(5):545-50. PubMed ID: 23273395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One year clinical outcomes in patients with chronic kidney disease treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O; Helft G; Le Feuvre C
    Int J Cardiol; 2011 Mar; 147(2):307. PubMed ID: 21215476
    [No Abstract]   [Full Text] [Related]  

  • 8. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
    Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of peripheral vascular disease on short- and long-term outcomes in patients undergoing non-emergent percutaneous coronary intervention in the drug-eluting stent era.
    Midwall S; Swaminathan RV; Charitakis K; Kim LK; Gordin J; Hriljac I; Minutello RM; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2013 Mar; 25(3):132-6. PubMed ID: 23468442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.
    Damman P; Abdel-Wahab M; Möllmann H; Richardt G; Chevalier B; Barragan P; Tijssen JG; Underwood P; Hamm CW
    J Invasive Cardiol; 2012 Oct; 24(10):495-502. PubMed ID: 23043032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease.
    Niccoli G; Sgueglia GA; Cosentino N; Piro M; Toma A; Cataneo L; Fracassi F; Porto I; Leone AM; Burzotta F; Trani C; Crea F
    Eur J Prev Cardiol; 2012 Oct; 19(5):914-26. PubMed ID: 21840968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
    Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW
    Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents.
    Pilgrim T; Kalesan B; Zanchin T; Pulver C; Jung S; Mattle H; Carrel T; Moschovitis A; Stortecky S; Wenaweser P; Stefanini GG; Räber L; Meier B; Jüni P; Windecker S
    EuroIntervention; 2013 Jan; 8(9):1061-71. PubMed ID: 23339812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous coronary intervention in patients with previous coronary artery bypass grafting (from the j-Cypher Registry).
    Yamaji K; Kimura T; Morimoto T; Nakagawa Y; Inoue K; Nobuyoshi M; Mitsudo K;
    Am J Cardiol; 2013 Oct; 112(8):1110-9. PubMed ID: 23827399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Percutaneous coronary revascularization in patients with renal insufficiency].
    Rodríguez-Capitán J; Domínguez-Franco A; Muñoz-García A; Hernández-García J; Alonso-Briales J; Jiménez-Navarro M
    Med Clin (Barc); 2012 Jun; 139(1):10-2. PubMed ID: 22257607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial.
    Diletti R; Garcia-Garcia HM; Bourantas CV; van Geuns RJ; Van Mieghem NM; Vranckx P; Zhang YJ; Farooq V; Iqbal J; Wykrzykowska JJ; de Vries T; Swart M; Teunissen Y; Negoita M; van Leeuwen F; Silber S; Windecker S; Serruys PW;
    Heart; 2013 Sep; 99(17):1267-74. PubMed ID: 23800571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
    Onuma Y; Miquel-Hebert K; Serruys PW;
    EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial optical coherence tomography-based observation of strut coverage on drug-eluting stent crossing side-branch vessels.
    Lee SY; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    J Invasive Cardiol; 2012 Nov; 24(11):569-73. PubMed ID: 23117310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.